Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 5/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.58 |
| ▸ | HRH2 | P25021 | 11/20 | 0.58 |
| ▸ | HRH1 | P35367 | 11/20 | 0.58 |
| ▸ | MMP3 | P08254 | 5/20 | 0.55 |
| ▸ | MMP1 | P03956 | 1/20 | 0.54 |
| ▸ | MMP9 | P14780 | 1/20 | 0.54 |
| ▸ | MMP13 | P45452 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9167569 | 0.95 | MMP3 (0.57) | MMP2HRH3HRH2HRH1MMP3 | |
| SCHEMBL1428967 | 0.94 | HRH3 (0.53) | MMP2HRH3HRH2HRH1MMP3 | |
| SCHEMBL17749614 | 0.93 | HDAC1 (0.58) | MMP2HRH3HRH2HRH1MMP3 | |
| SCHEMBL2201281 | 0.93 | HDAC1 (0.58) | MMP2HRH3HRH2HRH1MMP3 | |
| SCHEMBL9227146 | 0.93 | HDAC1 (0.58) | MMP2HRH3HRH2HRH1MMP3 | |
| SCHEMBL5097451 | 0.93 | HDAC1 (0.58) | MMP2HRH3HRH2HRH1MMP3 | |
| SCHEMBL6709272 | 0.93 | HDAC1 (0.58) | MMP2HRH3HRH2HRH1MMP3 | |
| SCHEMBL9227809 | 0.93 | HDAC1 (0.58) | MMP2HRH3HRH2HRH1MMP3 | |
| SCHEMBL9224982 | 0.93 | HDAC1 (0.58) | MMP2HRH3HRH2HRH1MMP3 | |
| SCHEMBL5096630 | 0.93 | HDAC1 (0.58) | MMP2HRH3HRH2HRH1MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2928985-B1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2016-12-21 | — | — | EP | disclosed |
| US-20160229795-A1 | COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2016-08-11 | — | — | US | disclosed |
| US-20150315470-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2015-11-05 | — | — | US | disclosed |
| WO-2015043713-A1 | COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2015-04-02 | — | — | WO | disclosed |
| WO-2014090372-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2014-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229795-A1 | COMPOUNDS AND MESOGENIC MEDIA | MTX1, NEFM, MTX2 | MMP2 185/4885HRH3 3865/4885HRH2 3986/4885 |
| US-20150315470-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | SP1, FOXM1, S100A11 | MMP2 1154/4885HRH3 2096/4885HRH2 3001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.